Cargando…
Economic Burden of Myocardial Infarction Combined With Dyslipidemia
Background: Dyslipidemia is a common comorbidity and an important risk factor for myocardial infarction (MI). This study aimed to examine the economic burden of MI combined with dyslipidemia in China. Methods: Patients who were hospitalized due to MI combined with dyslipidemia in 2016 were enrolled....
Autores principales: | Chen, Pingyu, Zhang, Mengran, Zhang, Yan, Su, Xi, Chen, Jiyan, Xu, Biao, Tao, Jianhong, Wang, Zhen, Ma, Aixia, Li, Hongchao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933193/ https://www.ncbi.nlm.nih.gov/pubmed/33681139 http://dx.doi.org/10.3389/fpubh.2021.648172 |
Ejemplares similares
-
Predictors of Quality of Life in Patients With Myocardial Infarction Combined With Dyslipidemia
por: Zhang, Mengran, et al.
Publicado: (2021) -
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022) -
Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021) -
Study on the Economic Burden of Neurodevelopmental Diseases on Patients With Genetic Diagnosis
por: Xie, Donghua, et al.
Publicado: (2022) -
Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
por: Ma, Yue, et al.
Publicado: (2021)